Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

0.7998 +0.0742 (+10.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Ther ADR

< Previous 1 2 3 4 5 6 Next >
Adaptimmune Reports First Quarter Financial Results and Business Update
Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed... 
Via Newsfile
Earnings Preview For Adaptimmune Therapeutics
Via Benzinga
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell... 
Via Newsfile
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
The company bulks up its pipeline by regaining the rights to two of its clinical programs. 
Via The Motley Fool
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will... 
Via Newsfile
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Via Benzinga
Adaptimmune Therapeutics's Earnings Outlook
Via Benzinga
Expert Ratings for Adaptimmune Therapeutics
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via GlobeNewswire
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to... 
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of 
Via Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors. 
Via InvestorPlace
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed... 
Via Newsfile
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors... 
Via Newsfile
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in... 
Via Newsfile
Adaptimmune Announces Changes to Board of Directors
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in... 
Via Newsfile
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel --... 
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial... 
Via Newsfile
Exposures Product Safety
Credit Suisse, Autodesk And Other Big Losers From Wednesday
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after... 
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Upgrades 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.